Cluenex
Log inStart free
All stocks · Healthcare · Medical Devices

LivaNova LIVN

LivaNova scores average on business quality (5.5 of 10). Here is why, in plain words, and what our sealed record shows.

Last price$76.39Oct 9, 2026
Business qualityAverage
Next earningsNov 4, 2026, before the open
Insiders, 90 daysSelling

Why it matters

  1. What LivaNova does

    LivaNova designs and sells neuromodulation and cardiovascular medical devices, collecting revenue from hospitals and clinics treating drug-resistant epilepsy and cardiac conditions. The company is leaning into new product innovations and operating leverage to lift its profit outlook.

  2. What it does best

    LivaNova dominates vagus nerve stimulation for drug-resistant epilepsy, anchoring its position with a gross margin of 68.1%. This high margin reflects specialized tech that hospitals cannot easily swap out due to strict clinical protocols.

  3. The main risk

    Execution slips in product rollouts or unexpected clinical delays could pinch margins, especially with an operating margin resting at 13.8% and a modest sector rank of 40 for profitability.

Quality, check by check

Scored against its own industry, from company filings.

ProfitabilityWeak

Operating margins stand at 13.8% with an FCF margin of 10.1%, showing moderate profitability that expands slowly as revenue scales.

MoatFair

Patents and clinical relationships lock in hospital buyers, backed by a gross margin in the 61st sector percentile. Rivals face years of trials to replicate this setup.

GrowthSteady

Revenue grew at 10.8% to hit $1.4B, marking an acceleration from prior years where growth hovered closer to single digits.

Financial healthFair

Debt-to-equity sits at 0.3x with interest coverage at 5.6x, leaving debt costs manageable. Free cash flow reached $148M, showing a softer profile overall.

Insiders

Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.

3 sold $800K outside pre-planned sales.

Our sealed record on LIVN

Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.

The first sealed verdicts appear here on Oct 11, 2026.

Questions

Is LIVN a good business?

LivaNova scores average on the Cluenex quality check (5.5 of 10), measured against its own industry. Profitability is weak, moat fair, growth steady and financial health fair.

Are insiders buying LIVN?

In the last 90 days of SEC Form 4 filings: 3 sold $800K outside pre-planned sales.

When does LIVN report earnings?

Nov 4, 2026, before the open.

For members

See LIVN today

  • Today's verdict on LIVN, and why
  • Fair value with cautious, base and optimistic cases
  • The exact price that would change the verdict
  • Which stocks each signal names, the night it fires
Open in Cluenex Free to start. First month of Core free.

Cite this page: Cluenex, “LivaNova (LIVN)”, https://cluenex.com/stocks/livn/, data as of Oct 10, 2026.